STRIDES PHARMA SCIENCE LIMITED

BSE: STAR532531ISIN INE939A01011

Healthcare
Pharmaceuticals
BSE 1000

Share price

₹1,011.90-27.35 (-2.63%)

as of 4 Nov 2026

Prices adjusted for splits and bonuses; cash dividends excluded. Volume shows actual shares traded. Earlier history is omitted pending corporate-action verification.

52W high: ₹1,260.10
52W low: ₹769.60
Off 52W high: -19.70%
1M return: -6.81%
3M return: +4.42%
6M return: -7.90%
1Y return: +5.14%
20D avg volume: 19,930
50 DMA: ₹1,097.07
200 DMA: ₹1,020.61

Key ratios Consolidated

Market cap: ₹9,327 Cr
Current price: ₹1,011.90
52W high / low: ₹1,260.10 / ₹769.60
Face value: ₹10.00
P/E: 14.64
P/B: 2.73
EPS (TTM): ₹69.11
Book value / share: ₹370.66
ROE: —
ROCE: 21.00%
Operating margin: —
Net margin: —
Debt / equity: 0.53
Net debt: ₹1,480 Cr
Interest cover: 4.74
Dividend yield: 0.49%
Dividend / share (TTM): ₹5.00
Payout: 7.23%
Cash conversion cycle: 121.2 days

Financials

Metric	Q2 FY27	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24
Income statement
	1,430	1,265	1,323	1,195	1,221	1,120	1,190	1,154	1,201	1,088	1,084	1,038
	4.08	4.89	8.13	106.86	27.14	8.58	11.98	5.62	28.41	12.72	13.55	8.75
	1,434	1,270	1,332	1,302	1,248	1,128	1,202	1,159	1,230	1,100	1,070	1,046
	1,283	1,133	1,179	1,053	1,085	998.01	1,072	1,044	1,098	999.51	984.22	974.37
	564.95	414.71	408.88	459.71	429.76	260.58	269.73	476.58	448.85	364.21	353.84	375.13
	180.97	166.38	127.45	71.38	41.80	120.91	231.60	133.77	55.33	79.44	112.64	50.66
	238.27	242.99	247.11	229.54	226.78	225.52	222.86	215.64	219.41	212.17	199.17	184.49
	46.54	40.56	41.58	43.38	46.13	47.46	50.32	52.18	82.15	80.39	80.16	79.28
	57.22	56.40	53.25	50.62	49.64	48.89	48.86	48.42	50.52	48.59	49.76	51.23
	311.12	297.46	300.40	266.22	247.22	231.86	250.69	247.59	247.97	237.91	238.91	238.12
	151.24	137.70	153.01	248.81	162.94	130.31	130.66	115.32	131.54	100.71	86.27	72.05
	-1.70	63.20	-6.41	-3.30	-8.77	-8.37	-27.41	-2.43	-3.87	-3.74	-8.07	-10.07
	149.54	200.90	146.60	245.51	154.16	121.94	103.25	112.89	127.67	96.98	78.20	61.99
	16.32	34.12	18.77	37.35	21.59	16.45	20.76	23.80	21.20	16.86	19.25	10.10
	134.12	165.49	129.28	208.12	131.52	105.59	85.62	90.04	93.66	68.31	10.44	54.06
	14.19	17.02	13.77	21.93	13.84	10.81	8.92	9.56	10.14	7.64	1.97	-0.49
Key metrics
	253.30	297.86	241.43	339.51	249.93	218.29	202.43	213.49	260.34	225.96	208.12	192.50
	17.70%	23.50%	18.20%	28.40%	20.50%	19.50%	17.00%	18.50%	21.70%	20.80%	19.20%	18.60%
	9.40%	13.10%	9.80%	17.40%	10.80%	9.40%	7.20%	7.80%	7.80%	6.30%	1.00%	5.20%
	4.50%	—	4.70%	—	5.50%	—	4.40%	—	—	—	—	—
	17.10%	13.00%	11.20%	3.60%	1.60%	3.00%	9.80%	11.20%	—	—	—	—
	2.00%	56.70%	51.00%	131.10%	40.40%	54.60%	720.10%	66.60%	—	—	—	—

Metric	TTM	FY26	FY25	FY24	FY23	FY22
Income statement
	5,213	4,859	4,565	4,051	3,688	3,070
	123.96	150.71	58.72	39.70	90.33	131.99
	5,337	5,009	4,624	4,091	3,779	3,202
	4,646	4,314	4,204	3,843	3,763	3,500
	1,848	1,559	1,476	1,341	1,442	1,091
	546.18	361.54	688.08	283.45	187.87	316.11
	957.91	928.96	862.76	751.12	732.02	646.91
	172.06	178.54	248.85	314.44	261.14	176.74
	217.49	202.40	192.26	220.68	243.25	233.01
	1,175	1,046	919.80	916.23	899.30	931.35
	690.76	695.06	420.42	247.84	16.11	-297.88
	51.79	-26.84	64.66	-189.04	-17.03	-243.82
	742.55	668.22	485.08	58.79	-0.92	-541.70
	106.56	94.17	77.52	31.59	55.30	178.26
	637.01	574.52	3,598	-94.31	-212.33	-474.25
	66.91	60.34	390.54	-13.72	-24.56	-51.28
Key metrics
	1,132	1,049	926.19	593.91	503.47	-131.95
	21.72%	21.60%	20.30%	14.70%	13.70%	-4.30%
	12.22%	11.80%	78.80%	-2.30%	-5.80%	-15.40%
	—	21.00%	21.20%	—	—	—
	11.28%	6.40%	12.70%	9.80%	20.10%	—
	54.33%	-84.00%	3,914.60%	55.60%	55.20%	—
	—	279.58	441.87	—	—	—
	—	1.22	0.19	—	—	—
	—	0.53	0.69	—	—	—
	—	1,480	1,683	—	—	—
	—	121.2	115.8	—	—	—
Balance sheet
	—	6,927	6,049	—	—	—
	—	3,613	3,099	—	—	—
	—	188.70	112.56	—	—	—
	—	1,289	1,203	—	—	—
	—	1,635	1,278	—	—	—
	—	—	227.37	—	—	—
	—	992.43	880.69	—	—	—
	—	1,310	1,032	—	—	—
	—	2,895	2,592	—	—	—
	—	1,669	1,796	—	—	—
	—	1,116	1,224	—	—	—
	—	552.32	571.24	—	—	—
	—	3,149	2,586	—	—	—
Cash flow
	—	702.52	684.37	—	—	—
	—	-173.04	-89.69	—	—	—
	—	-453.41	-642.58	—	—	—
	—	422.94	242.50	—	—	—

Metric	Q2 FY27	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24
Income statement
	659.91	582.65	605.74	553.63	522.15	498.62	555.96	550.92	609.96	554.75	617.63	520.01
	1.38	1.48	3.97	103.24	14.09	1.76	12.12	2.43	23.55	11.83	29.63	8.69
	661.29	584.12	609.71	656.88	536.24	500.37	568.08	553.35	633.50	566.58	647.27	528.70
	644.06	575.77	583.20	522.07	510.86	483.97	539.76	531.95	619.06	560.92	594.41	519.89
	303.21	309.11	297.46	255.50	255.66	210.98	268.29	295.25	301.91	253.77	266.44	302.14
	44.54	50.95	15.89	17.75	30.01	15.75	10.65	32.27	7.50	12.21	10.99	6.60
	107.92	102.40	95.94	95.14	96.49	94.04	91.86	93.80	96.76	94.87	86.60	85.66
	27.76	28.51	26.66	27.25	29.41	30.45	29.36	34.21	50.15	46.88	46.77	44.47
	27.81	25.73	25.19	22.39	21.51	22.14	22.37	20.92	21.98	20.32	20.81	21.06
	115.80	114.86	121.95	104.95	81.42	95.16	113.92	103.45	134.63	119.41	128.72	96.55
	17.23	8.36	26.51	134.80	25.39	16.40	28.32	21.39	14.44	5.66	52.85	8.81
	0.00	76.40	0.00	0.00	0.00	0.00	0.00	-0.02	-0.01	—	-0.07	-5.29
	17.23	84.76	26.51	134.80	25.39	16.40	28.32	21.38	14.43	5.66	52.78	3.52
	7.97	11.83	10.15	12.91	-6.65	3.06	12.20	6.44	0.88	1.75	0.89	0.98
	9.26	72.93	16.35	121.89	32.04	13.35	16.13	14.94	15.31	3.92	53.66	2.54
	1.00	7.91	1.77	13.22	3.48	1.45	1.75	1.62	1.66	0.43	5.84	0.28
Key metrics
	72.80	139.00	78.36	184.44	76.31	68.99	80.05	76.51	86.56	72.86	120.36	69.05
	11.00%	23.90%	12.90%	33.30%	14.60%	13.80%	14.40%	13.90%	14.20%	13.10%	19.50%	13.30%
	1.40%	12.50%	2.70%	22.00%	6.10%	2.70%	2.90%	2.70%	2.50%	0.70%	8.70%	0.50%
	1.20%	—	1.50%	—	1.60%	—	1.70%	—	—	—	—	—
	26.40%	16.90%	9.00%	0.50%	-14.40%	-10.10%	-10.00%	5.90%	—	—	—	—
	-71.10%	446.30%	1.40%	715.90%	109.30%	240.60%	-69.90%	488.20%	—	—	—	—

Metric	TTM	FY26	FY25	FY24	FY23	FY22
Income statement
	2,402	2,180	2,139	2,153	1,854	1,979
	110.07	123.06	46.19	72.31	84.07	123.48
	2,512	2,303	2,186	2,226	1,939	2,102
	2,325	2,100	2,108	2,151	1,988	2,081
	1,165	1,020	1,048	1,073	1,020	935.42
	129.13	79.40	62.63	29.23	24.47	51.83
	401.40	381.60	377.59	335.21	267.01	272.09
	110.18	113.77	145.91	167.93	138.68	74.24
	101.12	91.24	84.61	84.67	93.62	104.37
	457.56	403.47	415.86	456.30	423.40	526.32
	186.90	203.10	78.11	74.99	-49.76	21.51
	76.40	0.00	-0.03	-5.37	-15.00	—
	263.30	203.10	78.08	69.62	-64.76	21.51
	42.86	19.47	18.93	4.13	69.44	158.68
	220.43	183.63	2,886	65.49	4.68	180.19
	23.90	19.92	313.68	7.20	0.52	20.08
Key metrics
	474.60	408.11	308.60	322.22	167.54	200.12
	19.76%	18.70%	14.40%	15.00%	9.00%	10.10%
	9.18%	8.40%	134.90%	3.00%	0.30%	9.10%
	—	8.90%	6.60%	—	—	—
	12.89%	1.90%	-0.60%	16.10%	-6.30%	—
	188.29%	-93.60%	4,307.10%	1,299.40%	-97.40%	—
	—	109.28	255.28	—	—	—
	—	1.51	0.15	—	—	—
	—	0.35	0.36	—	—	—
	—	1,132	1,150	—	—	—
	—	237.0	238.9	—	—	—
Balance sheet
	—	5,396	5,031	—	—	—
	—	2,374	2,146	—	—	—
	—	16.17	6.33	—	—	—
	—	1,521	1,453	—	—	—
	—	580.27	431.71	—	—	—
	—	192.13	170.65	—	—	—
	—	634.20	606.42	—	—	—
	—	685.59	484.85	—	—	—
	—	1,840	1,630	—	—	—
	—	1,148	1,156	—	—	—
	—	974.89	1,029	—	—	—
	—	173.25	127.37	—	—	—
	—	3,284	3,193	—	—	—
Cash flow
	—	277.85	421.48	—	—	—
	—	-69.07	-137.59	—	—	—
	—	-198.93	-370.32	—	—	—
	—	168.57	166.20	—	—	—

Compounded growth

Standalone

Sales CAGR 3Y: +5.54%
Sales CAGR 5Y: —
Profit CAGR 3Y: +239.81%
Profit CAGR 5Y: —
Sales YoY (TTM): +12.89%
Profit YoY (TTM): +188.29%

Consolidated

Sales CAGR 3Y: +9.62%
Sales CAGR 5Y: —
Profit CAGR 3Y: —
Profit CAGR 5Y: —
Sales YoY (TTM): +11.28%
Profit YoY (TTM): +54.33%

Compounded from reported annual figures. We publish no share-price CAGR: our prices are as-traded, so one would be wrong across every split and bonus issue.

Shareholding as of 30 Sep 2026

Promoter holding: 29.00%

Quarter	September 2026	June 2026
Promoter %	29.00%	27.92%

Holder	Type	Holding	Previous	Change
PRONOMZ VENTURES LLP	Promoter	19.62%	19.62%	0.00%
QUANT MUTUAL FUND - QUANT MULTI CAP FUND	Public	6.18%	—	—
ROUTE ONE OFFSHORE MASTER FUND, L.P.	Public	5.05%	5.05%	0.00%
KARUNA BUSINESS SOLUTIONS LLP	Promoter Group	3.50%	3.50%	0.00%
SBI LIFE INSURANCE CO. LTD	Public	3.47%	4.76%	-1.29%
ARUN KUMAR PILLAI	Promoter	3.10%	2.02%	+1.08%
BANDHAN BSE HEALTHCARE INDEX FUND	Public	2.79%	—	—
ROUTE ONE FUND I, L.P.	Public	2.17%	2.17%	0.00%
SATPAL KHATTAR	Public	1.60%	1.60%	0.00%
ABU DHABI INVESTMENT AUTHORITY - MONSOON	Public	1.46%	1.33%	+0.13%
K R RAVISHANKAR	Promoter	1.36%	1.36%	0.00%
AUTHUM INVESTMENT AND INFRASTRUCTURE LIMITED	Public	1.34%	1.28%	+0.06%
MUKUL MAHAVIR AGRAWAL	Public	1.12%	1.12%	0.00%
OMAN INDIA JOINT INVESTMENT FUND II	Public	1.10%	1.10%	0.00%
ISHARES CORE MSCI EMERGING MARKETS ETF	Public	1.02%	1.05%	-0.03%

Public shareholders are disclosed individually only above 1%.

Peer comparison

Company	Mkt cap (₹ Cr)	Price (₹)	P/E	ROCE	Sales YoY	Profit YoY	1Y return
Sun Pharmaceutical Industries Ltd.	4,26,112	1,776.00	38.78	17.90%	+12.13% TTM	+4.79% TTM	+4.92%
Divi's Laboratories Ltd.	2,66,424	10,036.00	91.09	19.00%	+16.35% TTM	+26.84% TTM	+47.61%
Torrent Pharmaceuticals Ltd.	1,79,908	4,730.00	85.71	9.10%	+42.06% TTM	-1.92% TTM	+32.24%
Laurus Labs Limited	1,24,601	2,306.10	93.53	19.70%	+23.03% TTM	+95.38% TTM	+134.59%
Zydus Lifesciences Limited	1,18,703	1,190.00	25.85	19.20%	+21.11% TTM	-2.51% TTM	+22.32%
Dr. Reddy's Laboratories Ltd.	1,14,513	1,372.00	41.50	13.90%	-3.53% TTM	-51.90% TTM	+14.26%
Cipla Ltd.	1,13,110	1,400.10	39.63	14.90%	-0.74% TTM	-47.48% TTM	-6.88%
Mankind Pharma Limited	1,04,631	2,533.15	46.22	13.70%	+13.27% TTM	+27.60% TTM	+6.91%
Aurobindo Pharma Ltd.	97,878	1,701.10	26.38	13.60%	+9.09% TTM	+9.48% TTM	+47.79%
Lupin Ltd	92,145	2,015.00	17.65	28.40%	+24.22% TTM	+20.10% TTM	+0.84%
Glenmark Pharmaceuticals ltd	70,608	2,501.85	39.27	16.20%	+32.94% TTM	+138.48% TTM	+35.48%
Alkem Laboratories Limited	62,054	5,190.00	28.15	18.80%	+13.36% TTM	-5.52% TTM	-8.38%
Abbott India Ltd. S	57,685	27,146.85	35.73	41.90%	+6.29% TTM	+11.18% TTM	-7.56%
Biocon Ltd.	56,061	344.00	134.63	2.90%	+5.70% TTM	-55.37% TTM	-9.53%
Gland Pharma Limited	52,105	3,157.70	46.16	13.70%	+17.57% TTM	+46.55% TTM	+65.09%
Ipca Laboratories Ltd.	50,051	1,973.15	36.40	16.40%	+10.59% TTM	+67.91% TTM	+52.33%
GlaxoSmithkline Pharmaceuticals Ltd.	42,904	2,532.60	37.42	55.40%	+12.12% TTM	+20.03% TTM	-4.84%
Ajanta Pharma Ltd.	41,406	3,313.55	32.79	29.40%	+25.01% TTM	+29.70% TTM	+26.89%
Emcure Pharmaceuticals Limited	41,254	2,174.55	37.75	25.10%	+21.12% TTM	+33.34% TTM	+64.07%
J.B. Chemicals & Pharmaceuticals Lt	38,731	2,412.25	47.77	21.90%	+5.87% TTM	+7.56% TTM	+45.79%
Sai Life Sciences Limited	32,855	1,546.30	90.80	18.10%	—	—	+67.49%
PIRAMAL PHARMA LIMITED	31,659	237.80	-151.21	0.80%	+9.43% TTM	-781.93% TTM	+18.60%
ACUTAAS CHEMICALS LIMITED	30,928	3,777.65	70.51	27.70%	+45.18% TTM	+95.78% TTM	+106.30%
Wockhardt Ltd	30,869	1,899.80	76.22	6.40%	+25.70% TTM	+894.12% TTM	+39.18%
RUBICON RESEARCH LIMITED	28,416	1,716.55	98.59	24.30%	—	—	+164.06%
STRIDES PHARMA SCIENCE LIMITED	9,327	1,011.90	14.64	21.00%	+11.28% TTM	+54.33% TTM	+5.14%

Filings & corporate actions

Recent announcements

Transcript of Earnings Call pertaining of Unaudited Financial Results of the Company for the quarter and half year ended September 30, 20262 Nov 2026 · Company Update / Earnings Call Transcript
Newspaper Advertisement - Unaudited Financial Results for the quarter and half year ended September 30, 202630 Oct 2026 · Company Update / Newspaper Publication
Audio Recording of Earnings Call pertaining to unaudited Financial Results for the quarter and half year ended September 30, 202630 Oct 2026 · Company Update / Analyst / Investor Meet
Appointment of Mr. Biren Gabhawala (DIN:03091772) as a Non-Executive Independent Director of the Company with effect from November 1, 2026.29 Oct 2026 · Company Update / Change in Directorate
Allotment of Equity shares pursuant to exercise of Stock Options.29 Oct 2026 · Company Update / Allotment of ESOP / ESPS
Earnings presentation for the quarter and half year ended September 30, 2026.29 Oct 2026 · Company Update / Investor Presentation
Strides Delivers Strong Performance with Q2FY27 Revenue at Rs. 14.297m, Grew 17% YoY. Ex-US Markets Up 31% YoY; EBITDA Up 8% YoY to Rs. 2,509m, Crossing Rs. 2,500m in a Quarter for the First Time.29 Oct 2026 · Company Update / Press Release / Media Release
Financial Results for the quarter and half year ended Sept 30, 202629 Oct 2026 · Result / Financial Results
Earnings Call to discuss the Unaudited Financial Results of the Company for the quarter and half year ended September 30, 202623 Oct 2026 · Company Update / Analyst / Investor Meet
Strides Pharma Science Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/10/2026 ,inter alia, to consider and approve This is to inform you ....23 Oct 2026 · Board Meeting / Board Meeting
Certificate in terms of regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended September 30, 20267 Oct 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Closure of Trading Window for the quarter ended September 30, 202624 Sep 2026 · Insider Trading / SAST / Closure of Trading Window
Strides'' Sustainability Report for FY2623 Sep 2026 · Company Update / General
Completion of USFDA Inspection at the Company''s Formulation Facility at Alathur11 Sep 2026 · Company Update / General
Strides receives USFDA Establishment Inspection Report (EIR) for flagship facility in Bengaluru19 Aug 2026 · Company Update / Press Release / Media Release
Voting results along with Scrutinizers report for 35th AGM.18 Aug 2026 · AGM/EGM / AGM
Proceedings of 35th Annual General Meeting of the Company14 Aug 2026 · AGM/EGM / AGM
Transcript of Earnings Call pertaining to Unaudited Financial Results of the Company for the quarter ended June 30, 2026.3 Aug 2026 · Company Update / Analyst / Investor Meet
Newspaper advertisement - Unaudited Financial Results for the quarter ended June 30, 20261 Aug 2026 · Company Update / Newspaper Publication
Audio Recording of Earnings Call dated July 31, 2026, pertaining to unaudited financial results for Q1 FY2731 Jul 2026 · Company Update / Analyst / Investor Meet
Earnings Presentation for the quarter ended June 30, 202631 Jul 2026 · Company Update / Investor Presentation
Strides Delivers Steady Performance with Q1FY27; Revenue at Rs. 12,654m, Grew 13% YoY; Ex-US Markets Grew 17% YoY31 Jul 2026 · Company Update / Press Release / Media Release
Outcome of Board Meeting of the Company held on July 31, 202631 Jul 2026 · Result / Financial Results
Earnings Call to discuss the Unaudited Financial Results of the Company for the quarter ended June 30, 202624 Jul 2026 · Company Update / Analyst / Investor Meet
Strides Pharma Science Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 31/07/2026 ,inter alia, to consider and approve the unaudited financial ....24 Jul 2026 · Board Meeting / Board Meeting
Business Responsibility and Sustainability Report for FY 202621 Jul 2026 · Others / Business Responsibility and Sustainability Reporting (BRSR)
35th Annual General Meeting is scheduled to be held on Friday, August 14, 2026 at 12:15 hrs IST21 Jul 2026 · AGM/EGM / AGM
Annual Report for FY 2025-2621 Jul 2026 · Others / Reg. 34 (1) Annual Report
35th Annual General Meeting is scheduled on Friday, August 14, 2026 at 12:15 HRS IST.21 Jul 2026 · AGM/EGM / AGM
Company has fixed the Record Date for Final Dividend for FY26 as Friday, July 31, 202620 Jul 2026 · Corp. Action / Record Date
Certificate in terms of regulation 74(5) of SEBI (Depositories and Participants) Regulations, 20188 Jul 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Update on Completion of Transaction relating to Pivot Path.3 Jul 2026 · Company Update / Restructuring
Strides Partners with Ascent Capital to Unlock Value in Pivot Path27 Jun 2026 · Company Update / Restructuring
Strides Partners with Ascent Capital to Unlock Value in Pivot Path27 Jun 2026 · Company Update / Press Release / Media Release
Intimation regarding closure of Trading Window for the quarter ended June 30, 2026.24 Jun 2026 · Insider Trading / SAST / Closure of Trading Window
Intimation of Schedule of Analyst/ Institutional Investors Meet8 Jun 2026 · Company Update / Analyst / Investor Meet
Reminder to Shareholders regarding Unclaimed Dividends and Transfer to IEPF1 Jun 2026 · Company Update / General
Intimation of Effective Date for Scheme of Demerger involving Arco Lab Private Limited ("Arco Lab") and ("Pivot Path Private Limited").1 Jun 2026 · Company Update / General
Schedule of Analyst/ Institutional Investor''s Meeting - as enclosed.28 May 2026 · Company Update / Analyst / Investor Meet
Schedule of Analyst/ Institutional Investor''s Meet - as enclosed.28 May 2026 · Company Update / Analyst / Investor Meet

Corporate actions

Purpose	Ex date	Record date	Payment date
Final Dividend - Rs. - 5.0000	31 Jul 2026	31 Jul 2026	—
Final Dividend - Rs. - 4.0000	22 Jul 2025	22 Jul 2025	—
Spin Off	6 Dec 2024	6 Dec 2024	—
Final Dividend - Rs. - 2.5000	9 Sep 2024	9 Sep 2024	—

Board meetings

29 Oct 2026 Board Meeting - Financial Results
31 Jul 2026 Board Meeting - Financial Results